ATE456055T1 - Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden - Google Patents

Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden

Info

Publication number
ATE456055T1
ATE456055T1 AT06765356T AT06765356T ATE456055T1 AT E456055 T1 ATE456055 T1 AT E456055T1 AT 06765356 T AT06765356 T AT 06765356T AT 06765356 T AT06765356 T AT 06765356T AT E456055 T1 ATE456055 T1 AT E456055T1
Authority
AT
Austria
Prior art keywords
brain damage
diagnostic methods
diseases related
polypeptide
subject
Prior art date
Application number
AT06765356T
Other languages
English (en)
Inventor
Denis Francois Hochstrasser
Jean-Charles Sanchez
Original Assignee
Univ Geneve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Geneve filed Critical Univ Geneve
Application granted granted Critical
Publication of ATE456055T1 publication Critical patent/ATE456055T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
AT06765356T 2005-07-14 2006-07-14 Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden ATE456055T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0514435A GB2428240A (en) 2005-07-14 2005-07-14 Diagnostic method for brain damage-related disorders
PCT/GB2006/050207 WO2007007129A2 (en) 2005-07-14 2006-07-14 Diagnostic method for brain damage-related disorders

Publications (1)

Publication Number Publication Date
ATE456055T1 true ATE456055T1 (de) 2010-02-15

Family

ID=34897198

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06765356T ATE456055T1 (de) 2005-07-14 2006-07-14 Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden

Country Status (10)

Country Link
US (1) US9028825B2 (de)
EP (1) EP1902319B1 (de)
JP (2) JP5281397B2 (de)
AT (1) ATE456055T1 (de)
AU (1) AU2006268034B2 (de)
CA (1) CA2613991C (de)
DE (1) DE602006011896D1 (de)
ES (1) ES2336946T3 (de)
GB (1) GB2428240A (de)
WO (1) WO2007007129A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9929140D0 (en) * 1999-12-10 2000-02-02 Univ Geneve Diagnostic assay for stroke
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
EP2021792B1 (de) 2006-05-09 2013-02-27 The University Of British Columbia Gelöste arthritis-proteinmarker
DE102006048201A1 (de) * 2006-10-11 2008-04-17 Ganymed Pharmaceuticals Ag Autoantigene zur verbesserten Diagnose, Prognose und Therapie von entzündlichen neurologischen Erkrankungen
WO2009036336A2 (en) * 2007-09-12 2009-03-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomarkers for motor neuron disease
KR20180102215A (ko) 2007-11-27 2018-09-14 더 유니버시티 오브 브리티쉬 콜롬비아 관절염의 진단과 치료를 위한 14-3-3 에타 항체 및 이의 용도
KR20180090396A (ko) 2008-01-18 2018-08-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법
CN102171569A (zh) * 2008-05-09 2011-08-31 杜克大学 检测和治疗癌症的自身抗体
CA2733990C (en) 2008-08-11 2018-12-11 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
DK2389587T3 (en) * 2009-01-26 2014-03-03 Electrophoretics Ltd Diagnostic and prognostic methods related Alzheimer's Disease
AU2009339152B2 (en) * 2009-01-30 2015-11-19 Bio-Rad Europe Gmbh Method for the in vitro diagnosis of stroke
WO2010102412A1 (en) 2009-03-11 2010-09-16 Augurex Life Sciences Corporation Compositions and methods for characterizing arthritic conditions
JP2013501919A (ja) 2009-08-07 2013-01-17 アフィニマーク テクノロジーズ，インコーポレイテッド 脳脊髄液の免疫的識別のための装置および方法
WO2011032155A2 (en) 2009-09-14 2011-03-17 Banyan Biomarkers, Inc. Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
RU2422095C1 (ru) * 2009-12-11 2011-06-27 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ прогнозирования эффективности местной химиотерапии при лечении больных злокачественными опухолями головного мозга
WO2011106322A2 (en) * 2010-02-23 2011-09-01 The Govt. Of The U.S.A. As Represented By The Secretary, Department Of Health And Human Services. Biomarkers for acute ischemic stroke
GB201008541D0 (en) * 2010-05-21 2010-07-07 Univ Geneve Diagnostic methods
MX382244B (es) 2010-07-23 2025-03-13 Harvard College Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales
AU2011280936A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
AU2011280944A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting diseases or conditions using phagocytic cells
WO2012051519A2 (en) * 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
EP2653476B1 (de) * 2010-12-16 2017-04-26 National Institute of Advanced Industrial Science And Technology Verfahren zur anreicherung und trennung von rückenmarksflüssigkeitsglykoprotein, verfahren zum suchen von markern für erkrankungen des zentralnervensystems unter verwendung dieses verfahrens und marker für erkrankungen des zentralnervensystems
WO2012152970A1 (es) * 2011-05-06 2012-11-15 Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol Método de diagnóstico del ictus isquémico
WO2012155134A2 (en) 2011-05-12 2012-11-15 The Johns Hopkins University Assay reagents for a neurogranin diagnostic kit
JP6096781B2 (ja) * 2011-09-22 2017-03-15 バイオ−ラッド ラボラトリーズ，インコーポレイティド 生化学データ分析システム及び方法
PT2768851T (pt) 2011-10-21 2017-09-08 Augurex Life Sciences Corp Antigénios derivados de 14-3-3 citrulinada e utilizações dos mesmos no diagnóstico de artrite reumatoide
WO2013090285A1 (en) * 2011-12-14 2013-06-20 University Of Rochester Method of diagnosing mild traumatic brain injury
JP6392202B2 (ja) 2012-03-13 2018-09-19 ザ・ジョンズ・ホプキンス・ユニバーシティ 脳損傷または神経変性のバイオマーカーとしてのシトルリン化脳および神経タンパク質
EP2841945A4 (de) * 2012-04-24 2016-04-27 Astute Medical Inc Verfahren und zusammensetzungen zur diagnose und prognose von schlaganfall oder anderen hirnläsionen
SG11201408383SA (en) 2012-06-15 2015-01-29 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
US20140179805A1 (en) 2012-06-15 2014-06-26 Harry Stylli Methods of detecting diseases or conditions
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
EP2965086A4 (de) 2013-03-09 2017-02-08 Harry Stylli Verfahren zum nachweis von prostatakrebs
CN105659093A (zh) * 2013-06-28 2016-06-08 株式会社Mcbi 认知功能障碍疾病的生物标记物及使用该生物标记物的认知功能障碍疾病的检测方法
WO2015009907A1 (en) 2013-07-17 2015-01-22 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
WO2016040843A1 (en) 2014-09-11 2016-03-17 Harry Stylli Methods of detecting prostate cancer
FI20155280L (fi) 2015-04-15 2016-10-16 Medicortex Finland Oy Aivovamman prognostisia ja diagnostisia glykaanipohjaisia biomarkkereita
CN105506083B (zh) * 2015-12-24 2018-10-19 孙梅芬 Capg在制备诊断帕金森症产品中的用途
JP6947451B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
WO2018002362A1 (en) * 2016-06-30 2018-01-04 Randox Laboratories Ltd Measurement of fabp for diagnosis
KR102523237B1 (ko) 2016-08-03 2023-04-18 유니버시티 오브 사우스 플로리다 신경 장애의 치료를 위한 리일린 조성물
US20190257842A1 (en) * 2016-08-09 2019-08-22 Otsuka Pharmaceutical Co., Ltd. Method for assisting diagnosis of alzheimer's disease using urine biomarker
US10914748B2 (en) 2016-09-08 2021-02-09 UNIVERSITé LAVAL Erythrocyte-derived extracellular vesicles as a biomarker for clinically assessing Parkinson's disease
KR20250073510A (ko) * 2016-09-16 2025-05-27 다케다 파머수티컬 컴패니 리미티드 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커
JP2020500508A (ja) 2016-10-28 2020-01-16 バンヤン・バイオマーカーズ・インコーポレーテッド ユビキチンｃ末端ヒドロラーゼｌ１（ｕｃｈ−ｌ１）およびグリア線維酸性タンパク質（ｇｆａｐ）に対する抗体および関連する方法
KR102466369B1 (ko) * 2020-08-04 2022-11-14 서울대학교병원 자가면역 뇌염의 진단 방법
JP7569552B2 (ja) * 2021-01-29 2024-10-18 国立大学法人東北大学 認知症診断用のバイオマーカー
CN114966045A (zh) * 2022-05-07 2022-08-30 浙江大学 检测抗肌球蛋白轻链1-IgG自身抗体的试剂在制备检测血管内皮损伤的试剂盒中的应用
CN115166260B (zh) * 2022-07-11 2023-06-13 东南大学 血浆脑细胞来源外泌体中维生素d结合蛋白在诊断抑郁症中的应用
CN118624905B (zh) * 2023-07-31 2025-04-01 中国人民解放军总医院第一医学中心 一种糖尿病性肾病诊断的生物标志物和试剂盒及诊断设备
CN120820725B (zh) * 2025-09-17 2026-01-27 上海交通大学医学院附属仁济医院 胶质纤维酸性蛋白和乳酸脱氢酶a亚型在制备诊断颅脑创伤的试剂盒中的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017A (en) * 1845-05-01 Reid r
US3015A (en) * 1843-03-21 Improvement in gilding, silvering
GB225245A (en) * 1923-11-23 1924-12-24 British Thomson Houston Co Ltd Improvements in and relating to elastic fluid turbines
GB322063A (en) * 1928-10-29 1929-11-28 Godwin Stanley Oliver Improvements relating to automatic vehicle-controlled track-signalling devices
JPH09110713A (ja) * 1995-10-13 1997-04-28 Nippon Green Ueebu Kk グルタチオン−ｓ−トランスフェラーゼ活性化剤並びにそれを含む医薬品及び飲食物
CA2259122A1 (en) * 1996-06-17 1997-12-24 Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel ptp-20, pcp-2, bdp1, clk and sirp proteins and related products and methods
US6541615B1 (en) * 1996-11-15 2003-04-01 Max-Planck-Gellschaft Zur Foderung Der Wissenschaften E.V. SIRP proteins and uses thereof
CA2263063C (en) * 1999-02-26 2004-08-10 Skye Pharmatech Incorporated Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
AU1701001A (en) * 1999-11-30 2001-06-12 Eberhard-Karls-Universitat Tubingen Universitatsklinikum Antibodies against signal regulator proteins
GB9929140D0 (en) 1999-12-10 2000-02-02 Univ Geneve Diagnostic assay for stroke
GB2360089A (en) * 2000-03-10 2001-09-12 Univ Geneve Diagnostic assay for transmisible spongiform encephalopathies
CA2402314C (en) 2000-03-10 2009-12-08 Universite De Geneve Diagnostic assay for transmissible spongiform encephalopathies
US7608406B2 (en) * 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
EP2211181A1 (de) 2002-10-30 2010-07-28 Proteome Sciences Plc Methoden um übertragbare Spongiforme Enzephalopathien zu diagnostizieren
CA2532130C (en) * 2003-09-20 2016-07-19 Electrophoretics Limited Diagnostic method for brain damage-related disorders
EP1673465A4 (de) * 2003-09-29 2008-04-30 Biosite Inc Verfahren und zusammensetzungen zur sepsisdiagnose
GB0419124D0 (en) 2004-08-27 2004-09-29 Proteome Sciences Plc Methods and compositions relating to Alzheimer's disease
GB0421639D0 (en) 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
EP1825274B1 (de) 2004-12-07 2009-11-18 Electrophoretics Limited Monitorierung von Huntington's Disease

Also Published As

Publication number Publication date
EP1902319B1 (de) 2010-01-20
JP2009501333A (ja) 2009-01-15
JP2013092538A (ja) 2013-05-16
JP5281397B2 (ja) 2013-09-04
DE602006011896D1 (de) 2010-03-11
EP1902319A2 (de) 2008-03-26
CA2613991A1 (en) 2007-01-18
US20080220013A1 (en) 2008-09-11
WO2007007129A2 (en) 2007-01-18
GB2428240A (en) 2007-01-24
AU2006268034A1 (en) 2007-01-18
CA2613991C (en) 2017-03-07
GB0514435D0 (en) 2005-08-17
WO2007007129A3 (en) 2007-05-31
US9028825B2 (en) 2015-05-12
ES2336946T3 (es) 2010-04-19
AU2006268034B2 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
ATE456055T1 (de) Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
Oh et al. Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer's disease
DE602006014535D1 (de) Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen
JP2009501333A5 (de)
UA101167C2 (ru) Фармацевтическая композиция, предназначенная для лечения глазной болезни
WO2007136617A3 (en) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
WO2010084327A3 (en) Methods
WO2006073682A3 (en) Diagnostic test
WO2006081521A3 (en) Methods for diagnosis and intervention of hepatic disorders
WO2007080597A3 (en) Polynucleotide and polypeptide sequences and methods for diagnosis
DE602004024539D1 (de) Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben
EA201490883A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛА К α-СИНУКЛЕИНУ ДЛЯ ДИАГНОСТИКИ ПОВЫШЕННОГО УРОВНЯ α-СИНУКЛЕИНА В МОЗГЕ
ATE511651T1 (de) Transglutaminase 6 als diagnostischer indikator für autoimmunerkrankungen
WO2018038352A3 (ko) 치매진단용 자가항체 바이오마커 및 이를 이용한 치매진단 방법
WO2023004079A3 (en) Compositions and methods for detection of liver cancer
JP2013543581A5 (de)
AU2012313353A8 (en) Screening method
DK1756571T3 (da) Fremgangsmåde i realtid til detektering af akut inflammatoriske tilstande
ATE483982T1 (de) Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen
BR112013030646A2 (pt) uso diagnóstico de pró-somatostatina
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
ATE433115T1 (de) Timp-2 als ziel/marker des versagens von beta- zellen
BR112014007947A2 (pt) método para monitoramento, diagnóstico e/ou prognóstico de distúrbios relacionados à hipoxia usando nfat5
RU2014152876A (ru) Изоформы тропомиозина, связанные с болезнью альцгеймера и умеренными когнитивными нарушениями
WO2006117688A3 (en) Diagnosis of heart failure

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties